Up­dat­ed: Con­tro­ver­sial opi­oid Zo­hy­dro ER pulled from the mar­ket

As the Bel­gian phar­ma UCB re­cent­ly inked a $1.9 bil­lion deal to buy out Zo­genix and its top drug for epilep­sy, the com­pa­ny’s for­mer con­tro­ver­sial opi­oid has now been pulled from the mar­ket, ac­cord­ing to a Fed­er­al Reg­is­ter fil­ing by the FDA on Tues­day.

Hy­drocodone-based Zo­hy­dro ER — which ini­tial­ly won FDA ap­proval in 2013 de­spite not hav­ing abuse-de­ter­rent prop­er­ties and de­spite an 11-2 ad­comm vote against ap­proval — is now one of 29 new drug ap­pli­ca­tions from mul­ti­ple spon­sors that have de­cid­ed to pull their drugs from the mar­ket for var­i­ous rea­sons, ac­cord­ing to the fil­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA